Trials / Completed
CompletedNCT00162136
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
Phase I Study of Ixabepilone Administered as a 24-Hour Infusion in Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- R-Pharm · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixabepilone | Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2005-09-13
- Last updated
- 2020-11-02
- Results posted
- 2010-01-27
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00162136. Inclusion in this directory is not an endorsement.